Cogentix Medical to Participate in the 29th Annual ROTH Conference

Monday, March 6, 2017 General News J E 4

MINNEAPOLIS, March 6, 2017 /PRNewswire/ -- Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device company that develops, manufactures and markets innovative proprietary products for the urology market, today announced that the Company will participate in the 29th Annual ROTH Conference on Monday, March 13, 2017 and Tuesday, March 14, 2017. Darin Hammers, President and CEO, and Brett Reynolds, CFO will be available to meet with investors one-on-one at the conference and will make a presentation at the conference. 

On Monday, March 13, 2017 management will present at 7:00 a.m. Pacific Time (9:00 a.m. Central Time) at the Ritz Carlton in Dana Point, CA. A live webcast of the presentation will be available on the investor section of the Company's website at under "Events & Presentations."

A replay of the webcast will also be available on the Company's website following the event.

As a reminder, the Company will issue its fourth quarter financial results before the market open this Thursday, March 9, 2017 followed by a conference call and webcast to discuss the financial results the same day at 11:00 a.m. Eastern Time (10:00 a.m. Central Time).

About Cogentix MedicalCogentix Medical, Inc., headquartered in Minnetonka, Minnesota, with additional operations in New York, Massachusetts, The Netherlands and the United Kingdom, is a global medical device company.  We design, develop, manufacture and market products for flexible endoscopy with our unique product lines featuring a streamlined visualization system and proprietary sterile disposable microbial barrier, known as PrimeSight™, providing users with efficient and cost effective endoscope turnover while enhancing patient safety. We also commercialize the Urgent® PC Neuromodulation System, an FDA-cleared device that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). OAB is a chronic condition that affects approximately 42 million U.S. adults. The symptoms include urinary urgency, frequency and urge incontinence.  We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on Cogentix Medical and our products, please visit us at 'CGNT-G'

For Further Information: Cogentix Medical, Inc. Brett Reynolds, SVP and CFO 952-426-6152 EVC Group Doug Sherk/Brian Moore (Investors) 415-652-9100/310-579-6199


To view the original version on PR Newswire, visit:

SOURCE Cogentix Medical, Inc.



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Via Surgical Ltd. Signs Exclusive U.S Distribution...
Urinary Catheters Market Worth $5.51 Billion by 20...